KATELEEN PENDERGRASS: Open Payments
NPI 1184214124 · DALTON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,208 in 109 payments from 17 companies in 2025. Trend: 2023 $1,189 · 2024 $2,140 · 2025 $2,208
Food & beverage: $2,208
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $574 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $277 |
| Madrigal Pharmaceuticals | 10 | $251 |
| Janssen Biotech, Inc. | 9 | $142 |
| Aimmune Therapeutics, Inc. | 5 | $119 |
| Gilead Sciences, Inc. | 4 | $108 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| PFIZER INC. | 4 | $78 |
| QOL Medical, LLC | 2 | $59 |
Products named: XIFAXAN, ENTYVIO, REZDIFFRA, CREON, RINVOQ, LINZESS, TREMFYA, ZENPEP.
Industry payments across GA — which companies pay providers there.
